Standard BioTools (LAB) M&A announcement summary

Deal rationale and strategic fit

• Merger creates a clinical-stage biopharma with a deep pipeline in oncology, neurology, and immunology, leveraging Treeline's proven drug development team and Standard BioTools' capital resources.

• Strategic review determined the merger maximizes shareholder value and accelerates drug development, with Treeline offering the best value creation potential.

• Treeline brings expertise in precision medicines and a differentiated approach to drug development.

• Management from the target will lead the combined company, ensuring continuity and expertise.

Financial terms and conditions

• All-stock transaction values Standard BioTools at net cash plus $10 million, estimated at $460 million, with pre-merger Standard BioTools shareholders owning ~16% and Treeline shareholders ~84% of the combined company.

• Combined company expected to have over $900 million in cash at closing, funding operations and clinical programs into 2029.

• Pre-merger Standard BioTools shareholders to receive one contingent value right (CVR) per share for potential future payments, including up to $50 million in earn-outs/royalties.

Integration plans and timeline

• Combined company to operate as Treeline Biosciences, led by Treeline’s CEO, CSO, and CFO, and trade on Nasdaq under "TRLN".

• Board will have 12 directors: 10 from Treeline, 2 from Standard BioTools.

• Mass cytometry and microfluidics businesses to be divested or otherwise separated.

• Transaction expected to close in the second half of 2026, pending required approvals.